{
    "root": "189a64de-02e3-4e54-8325-31d3b00009df",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "DATROWAY",
    "value": "20250521",
    "ingredients": [
        {
            "name": "DATOPOTAMAB DERUXTECAN",
            "code": "GD2OWY1DTK",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16410"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        }
    ],
    "indications": {
        "text": "datroway indicated treatment adult patients unresectable metastatic , hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative ( ihc 0 , ihc 1+ ihc 2+/ish- ) breast cancer received prior endocrine-based therapy chemotherapy unresectable metastatic disease .",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous infusion . administer intravenous push bolus . sodium chloride injection , usp . ( 2.4 ) premedicate prevention infusion nausea vomiting . ( 2.2 ) recommended datroway 6 mg/kg given intravenous infusion every 3 weeks ( 21-day cycle ) disease progression unacceptable toxicity . ( 2.2 , 2.3 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.",
    "contraindications_original": "For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP. ( 2.4 ) Premedicate for prevention of infusion reactions and nausea and vomiting. ( 2.2 ) The recommended dosage of DATROWAY is 6 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. ( 2.2 , 2.3 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "DATROWAY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16410"
        }
    ]
}